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ABSTRACT
Motivation: The comprehensive information of small molecules and
their biological activities in PubChem brings great opportunities for
academic researchers. However, mining high-throughput screening
(HTS) assay data remains a great challenge given the very large
data volume and the highly imbalanced nature with only small
number of active compounds compared to inactive compounds.
Therefore, there is currently a need for better strategies to work
with HTS assay data. Moreover, as luciferase-based HTS technology
is frequently exploited in the assays deposited in PubChem,
constructing a computational model to distinguish and ﬁlter out
potential interference compounds for these assays is another
motivation.
Results: We used the granular support vector machines (SVMs)
repetitive under sampling method (GSVM-RU) to construct an SVM
from luciferase inhibition bioassay data that the imbalance ratio
of active/inactive is high (1/377). The best model recognized the
active and inactive compounds at the accuracies of 86.60% and
88.89 with a total accuracy of 87.74%, by cross-validation test and
blind test. These results demonstrate the robustness of the model
in handling the intrinsic imbalance problem in HTS data and it can
be used as a virtual screening tool to identify potential interference
compounds in luciferase-based HTS experiments. Additionally, this
method has also proved computationally efﬁcient by greatly reducing
the computational cost and can be easily adopted in the analysis of
HTS data for other biological systems.
Availability: Data are publicly available in PubChem with AIDs of
773, 1006 and 1379.
Contact: ywang@ncbi.nlm.nih.gov; bryant@ncbi.nlm.nih.gov
Supplementary information: Supplementary data are available at
Bioinformatics online.
1 INTRODUCTION
PubChem is a public repository for small molecules and their
biologicalproperties.ItwascreatedasacomponentoftheMolecular
Libraries Roadmap (Zerhouni, 2003) initiated by the National
Institutes of Health (NIH), which aims to discover chemical
probesthroughhigh-throughputscreening(HTS)ofsmallmolecules
to support chemical biology research (Zerhouni, 2003, 2006).
Currently, PubChem contains nearly 40 million unique chemical
structure and >50 million biological test results for >600 protein
∗To whom correspondence should be addressed.
targets.Analyzing the tremendous amount of biological activity data
in PubChem (Wang et al., 2009) (http://pubchem.ncbi.nlm.nih.gov)
remainsagreatchallengeforchemicalbiologyandcheminformatics
researchers.
Until recently, HTS data was largely owned by pharmaceutical
industrieswithonlylimitedaccesstothepublicresearchcommunity.
The comprehensive information of small molecules and their
biological activities in PubChem brings great opportunities for
academic researchers in the chemical biology, medicinal chemistry
and cheminformatics ﬁelds (Oprea et al., 2007; Ovaa and van
Leeuwen, 2008; Rosania et al., 2007; Southan et al., 2007) to
access and utilize large scale biological activity data to meet their
research goals. Several groups have attempted to develop methods
to analyze the data in this database (Guha and Schurer, 2008; Han
et al., 2008; Hur and Wild, 2008; Nakai et al., 2009; Xie and
Chen, 2008). Xie and Chen (2008) presented a strategy to select
a diverse compounds subset from the PubChem database. Cao et al.
(2008) developed a novel maximum common substructure-based
algorithm to predict drug-like compounds from PubChem bioassay
data. Rohrer and Baumann (2009) used a reﬁned nearest neighbor
analysis method to design benchmark datasets for virtual screening
based on information in the PubChem database.
However, working with the bioassay data in PubChem was
impeded by the imbalanced nature of HTS data. The data imbalance
problem exists in a broad range of experimental data, but only
recently has it attracted close attention from researchers (Barandela
et al., 2003; Weiss, 2004). Data imbalance occurs when one of the
classes in a dataset is represented by a very small number of samples
compared to the other classes, which is usually of great interest
(Barandela et al., 2003; Weiss, 2004). This issue might skew the
prediction accuracy of classiﬁcation models (Guha and Schurer,
2008; Hsieh et al., 2008), resulting in a weakened performance
of machine learning algorithms (Kang and Cho, 2006). In HTS
experiments, usually tens of thousands of compounds are screened,
but only a small fraction of tested compounds turns out to be active,
while the rest are inactive. Thus, HTS data is typically imbalanced
in general with a small ratio of active compounds to inactive ones.
Although many researchers (Guha and Schurer, 2008; Han et al.,
2008; Weis et al., 2008) have noticed this problem when using
the data in PubChem, to the best of our knowledge, there has
been no method reported to tackle this problem effectively. Han
et al. (2008) suggested that the data imbalance issue hindered the
bioactivity classiﬁcation accuracy. Guha et al. developed a random
forest ensemble model designed to alleviate the imbalance of the
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dataset in cell toxicity prediction (Guha and Schurer, 2008). Weis
et al. (2008) suggested the assay data be carefully selected from
PubChem to attempt to avoid using the imbalanced data in their
study.
Recently Tang et al. (2009) conducted an exhaustive comparative
study of the currently reported state-of-the-art methods and
proposed the granular sampling strategy to rebalance the originally
imbalanced data. In this study, we adopted this method to HTS data
analysis and investigate the strategies to mine the highly imbalanced
luciferase inhibition bioassay data in PubChem (PubChem AID of
773, 1006 and 1379). HTS experiments often employ luciferase
reporter genes and measure luminescence readouts (Fan and Wood,
2007).Theintrinsicluciferaseinhibitionpropertyofsmallmolecules
has been identiﬁed as one of the major screening artifacts (Auld
et al., 2009; Fan and Wood, 2007; Inglese et al., 2007) for
hits identiﬁcation in such HTS experiments. Therefore, we also
wanted to develop a virtual screening method to classify luciferase
inhibitors, and to ﬁlter out potential interference molecules in
luciferase-based HTS assays by taking the advantage of large scale
luciferase inhibition proﬁling screening results recently available in
the PubChem BioAssay database.
In addition to the data imbalance problem, HTS datasets can be
large, containing test results for hundreds of thousands of chemical
samples. It is a time-consuming process to build and optimize
statisticalmodelsusingsuchHTSdata.Therefore,anyimprovement
to computational efﬁciency could allow more data to be analyzed in
less time. Moreover, HTS data are also noisy in general (Diller and
Hobbs, 2004; Weis et al., 2008), and one needs to be cautious when
utilizing and analyzing the data. Strategies to address these issues
are also explored in this study.
2 METHODS
2.1 PubChem ﬁngerprint
PubChem ﬁngerprints were used to characterize chemical compounds
in this study. PubChem 2D chemical structure ﬁngerprint is an 881-
dimension binary (0/1) vector. Each bit represents a Boolean determination
of the absence or presence of a speciﬁc element, a type of ring
system, atom pairing, or atom environment (nearest neighbors), etc.
A detailed description of this ﬁngerprint system is available at
ftp://ftp.ncbi.nlm.nih.gov/pubchem/speciﬁcations/pubchem_ﬁngerprints.txt
2.2 Dataset
Three bioassay data entries in PubChem (PubChem BioAssay accession:
AID: 773, AID: 1006 and AID: 1379) for screening luciferase inhibitors
were used to construct the training dataset. The HTS experiments were
performed by two independent screening laboratories with AID: 1006 and
AID: 773 by the Burnham Center for Chemical Genomics, and AID: 1379
by the NIH Chemical Genomics Center (NCGC). The assay of AID: 773
contained 237 active and 33 inactive compounds out of 270 tested ones; the
assay of AID: 1006 contained 2976 active and 192590 inactive compounds
out of 195566 tested ones; and the assay of AID: 1379 contained 565
active, 197543 inactive and 982 inconclusive compounds out of 199080
tested compounds (Table 1). A majority of the compounds screened by the
assay of AID: 773 were also tested by the other two assays with 267 and
270 compounds in common with the assays of AID: 1006 and AID: 1379,
respectively.ThecompoundsscreenedbyassaysofAID:1006andAID:1379
also had a substantial overlap of 187138 compounds in common. However,
the bioactivity outcomes, i.e. active or inactive, of a single compound, did
not completely agree with each other in these three assays, which may be due
Table 1. Three assays of luciferase inhibitors used in this study
AIDa Active Inactive Inconclusive Total
773 237 33 0 270
1006 2976 192590 0 195566
1379 565 197543 982 199080
aPubChem BioAssay accession.
Table 2. Datasets used in this study
Number Type Active
compounds
Inactive
Compounds
Imbalance
ratioa
I Training 390 146934 1:377
II Blind testing 97 36733 1:379
aImbalance ratio denotes the ratio of active compounds to inactive ones in the dataset.
to experimental noise or artifacts in the HTS assay (Diller and Hobbs, 2004;
Weis et al., 2008). Therefore, we treated an active compound as a positive
sample if at least two assays considered it ‘active’. Similarly, we treated an
inactive compound as a negative sample by the conﬁrmation of at least two
assays. Compounds without conﬁrmed bioactivity outcome were excluded
in this study. A total of 487 positive and 183667 negative compounds
were included in the ﬁnal dataset, which was denoted as (487+183667) in
following descriptions. Other datasets, in this study, was similarly denoted
with the ﬁrst number represents the active compounds, with the second
number represents the inactive ones.
The ﬁnal dataset had an imbalance ratio of 1/377 (active/inactive), or
<0.3% active samples were contained in this dataset. To keep the data
imbalanced, we randomly split the whole dataset (487+183667) into
training data (dataset I) and blind testing data (dataset II) with the ratio
of 80/20 that 80% (390+146934) of the whole dataset (dataset I) was used
for constructing model and the other 20% (97+36733) (dataset II) for blind
testing (Table 2).
2.3 Modeling with support vector machine
We used support vector (SV) machine (SVM), Libsvm (Chang and Lin,
2001), for this study. According to the statistical learning theory (Corinna
and Vapnik, 1995), an optimal hyperplane is drawn by the SVM model to
separate active and inactive samples with a maximum distance between the
two classes. However, in an imbalanced situation that the majority class
exceeds the minority class by a signiﬁcant amount, the model likely pushes
the ideal hyperplane towards the minority class (Tang and Zhang, 2006; Wu
and Chang, 2005), resulting in classifying most observations into the class
in which the majority samples belong.
To avoid this distortion, we explored two methodologies in this study: one
was to rebalance the dataset with GSVM-RU method (Tang et al., 2009);
the other was to evaluate the model performance with vigorous evaluation
metrics independent of data distribution (Kubat and Matwin, 1997).
2.4 GSVM-RU undersampling method
The GSVM-RU method (Tang and Zhang, 2006; Tang et al., 2009) was
used to sample the majority class in order to rebalance the dataset. As
only SVs are important for SVM model classiﬁcation (Corinna and Vapnik,
1995) that removing non-SV samples does not substantially affect the model
performance. This method provides a mean to extract important samples
from the dataset and to eliminate the unimportant ones. Based on this theory,
GSVM-RU extracted the samples from the majority class according to their
contributions to the classiﬁcation in sampling process.
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The GSVM-RU method treated all positive samples as important due to
their rarity. However, for the negative samples, only SVs were considered
important. Because of the large amount of negative samples, it was hard to
extract all informative ones by using a single SVM, regardless of parameter
tuning. Despite this, a fraction of informative samples can still be identiﬁed
and extracted.These informative inactive samples (SVs) were removed from
the original dataset to form a smaller dataset.Anew SVM was then modeled
with the reduced dataset to identify another part of the informative negative
samples. This process was repeated as needed. Finally, the negative samples
extracted from the previous sampling runs were discarded, and only the
newly extracted inactive samples were retained and aggregated together with
the positive samples to produce the training set, on which the ﬁnal SVM
model is built. Upon the completion of sampling, a ﬁnal SVM was built and
optimized with linear and radius-based function (RBF) kernels. The ﬂow
chart of this strategy is shown in Figure S3 in the Supplementary Material.
2.5 Model evaluation
The 5-fold cross-validation method was used to evaluate the performance
of the SVM model. The whole dataset (dataset I) was randomly split into
ﬁve folds, with four folds used for training and the other fold for testing.
This process was repeated in turn and the ﬁnal average performance was
calculated. In addition to evaluate the generalization of the ﬁnal SVM model,
ablindtestwascarriedoutwithdatasetII,whichwasnotinvolvedintraining
process.
To consider the imbalance issue in this study, the receiver operating
characteristic (ROC) curve and geometric mean (G-mean) value were used,
which were suggested as good indicators dealing with such problems for
their independence from the sample distribution between classes (Barandela
et al., 2003; Kubat and Matwin, 1997). In addition, the common metrics of
sensitivity, speciﬁcity and overall accuracy (Li et al., 2007; Li and Lai, 2007)
were also calculated:
Sensitivity =
TP
(TP + FN)
(1)
Speciﬁcity =
TN
(TN + FP)
(2)
Overall accuracy =
(TP + TN)
(TP + FN + TN + FP)
(3)
where, TP, FP, TN and FN denote true positive, false positive, true negative
and false negative, respectively. G-mean that tries to maximize the accuracy
on each of the two classes while keeping them balanced is calculated as
following:
G-mean =

Sensitivity×Speciﬁcity (4)
3 RESULTS
3.1 Sampling the majority (inactive) data of dataset I
The training set (dataset I) contained 390 active compounds and
146934 inactive compounds, with <0.3% of the data active and
∼99.7% inactive resulting in a ratio of active to inactive of
1/377. Due to the rarity of active data, we assumed all 390
active compounds positive in the training set. For the majority
class (inactive), the data was sampled through multiple rounds of
sampling as described in Section 2. The signiﬁcant compounds after
sampling were identiﬁed to construct the negative data in the ﬁnal
trainingset.Basedonthepositiveandthesamplednegativedata,the
SVM model with linear and RBF kernels were built and optimized.
We used the GSVM-RU method to sample the inactive
compounds based on their signiﬁcance to the classiﬁcation. The
compounds identiﬁed in the previous round of sampling were
excluded in the subsequent round. Considering the efﬁciency, we
Fig. 1. The 5-fold cross-validation results of the training dataset in sampling
process. The squares in the solid line (blue) represent the G-mean values.
The ﬁlled circles in the dashed line (green) and the triangles in the dotted
line (red) represent speciﬁcity and sensitivity, respectively.
used the linear kernel of Libsvm with default parameters and 5-fold
cross-validation in this process. Meanwhile, sensitivity, speciﬁcity
and G-mean value were calculated to evaluate the performance of
each model (Fig. 1).
The G-mean value increased from around 60% to over 90% in the
sampling process (Fig. 1). Similarly, the sensitivity and speciﬁcity
improved gradually as well, with the speciﬁcity consistently 5–10%
higher than the corresponding sensitivity of each model. These data
indicate that the SVM model performance improved continuously
during the sampling process with the discrimination of inactive
compounds slightly better than that of active ones. Moreover, the
steady increasing of the model performance conﬁrmed that the
negative samples close to positive samples were being extracted
step by step.
In addition, we observed a variation of the performance of the
SVM model at the beginning of the sampling process. It is because
that there are many inactive compounds close to the active ones,
which are hard to be extracted for a single SVM model. However, as
thesamplingprocessiscontinued,itbecamerelativelystableandthe
results converged starting from sampling round 67.At this point, the
sample process was considered complete. The 358 sampled inactive
compounds obtained in the sampling process were used together
with the 390 active ones to produce the ﬁnal training set, which
was used to build and optimize a SVM model with linear and RBF
kernels.
3.2 Optimizing the SVM model
We used two kernels of linear and non-linear functions, i.e. RBF
kernel, to train the SVM model. For linear kernel, we tuned the
single parameter of cost C to optimize the SVM model; while for
RBFkernel,weoptimizedbothcostC andgammausingthegridtool
in Libsvm. The 5-fold cross-validation results of the linear model
and the non-linear model are shown in Table 3. The sensitivities of
these two models were similar (88.46%); however, the speciﬁcity of
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Table 3. The 5-fold cross-validation results of linear kernel SVM and RBF
kernel SVM
Kernel type Sensitivity (%) Speciﬁcity (%) Accuracy (%) G-mean (%)
Linear 88.46 91.34 89.84 89.89
RBF 88.46 94.97 91.58 91.66
Fig.2. TheROCcurvesoftheSVMwithlinearandRBFkernels.Thedashed
line (blue) and dotted line (red) represent RBF SVM model and linear SVM,
respectively. AUC (the area under the curve) is proportional to the model
performance.
the RBF SVM was slightly higher than that of the linear model, and
it outperformed the linear model by two percent with the highest
G-mean of 91.66%. For both the linear and the RBF SVMs, the
speciﬁcity exceeded the sensitivity, which may be due to the plenty
sampling of inactive sample space.
Similar results were observed in the ROC curves in Figure 2. The
dottedanddashedlinesofthecurverepresenttheperformanceofthe
linear SVM and RBF SVM, respectively. The AUC is proportional
to the model performance. The AUC of the RBF SVM (0.931) was
slightlygreaterthanthatofthelinearone(0.928).Thesedatasuggest
that both models performed well in the 5-fold cross-validation tests
with the RBF kernel slightly outperforming the linear kernel model.
In summary, both G-mean values and ROC curves show the good
performance of the SVM models in the 5-fold cross-validation, with
the RBF SVM model consistently producing slightly better results.
3.3 Evaluating models with blind test
For a statistical model, it may perform perfectly in training, but
poorlyintestingduetoover-ﬁtting,resultinginabadgeneralization.
Here, the generalization of the SVM model was evaluated with a
blind test where the testing dataset (dataset II) was excluded from
the training process in advance.This dataset contained 97 active and
36733 inactive compounds (Table 4). Both the linear and the RBF
SVMs successfully recognized 84 out of 97 active compounds, with
an equal accuracy of 86.60%. The performances for recognizing
inactive compounds were similar for both the linear SVM (88.36%)
Table 4. Blind testing resultsa
Kernel type Active accuracy (%) Inactive accuracy (%) G-mean (%)
Linear 86.60 (84/97) 88.36 (32457/36733) 87.48
RBF 86.60 (84/97) 88.89 (32651/36733) 87.74
aThe numbers in parentheses show how many samples are correctly recognized out of
the total testing ones.
Fig. 3. Distribution of the prediction results of testing samples. The blue
and red bars represent the correctly classiﬁed active compounds and inactive
compounds, respectively. While the yellow and green bars denote the
misclassiﬁed active samples and inactive samples instead, respectively.
and the RBF SVM (88.89%). The RBF SVM identiﬁed 32651 from
36733inactivecompounds,exceedingthelinearSVMby∼200hits.
The G-mean value shows a similar trend with the accuracies of the
linear SVM model and RBF SVM model as 87.48% and 87.74%,
respectively. These data indicate the RBF SVM performs slightly
better than the linear SVM. These blind testing results are very
close to those of the 5-fold cross-validation testing, suggesting that
both the linear and non-linear SVM have good generalizations.
We observed a clear separation of active and inactive compounds
by the optimized SVM model as shown in Figure 3.
3.4 Fingerprint features
WeusedPubChemﬁngerprinttocharacterizeeachofthecompounds
in this study. A PubChem ﬁngerprint contains 881 binary bits
that indicate the presence or absence of a certain group of
chemical features in a compound. We calculated the weight of each
feature using the linear SVM to examine their contributions to the
classiﬁcation. We found that the contribution to the classiﬁcation
varied among the observed chemical features. A positive score
signiﬁes that the feature is important to positive samples, while
a negative score signiﬁes the feature is important to the negative
samples. In general, the absolute value of a feature score is
proportional to its contribution to the SVM classiﬁcation.About half
of the features have a score between −0.1 and 0.1, indicating these
features are less important to the classiﬁcation (Fig. 4). The top 30
ﬁngerprint features with higher weight score for active compounds
arelistedinTableS1intheSupplementaryMaterial.Wenoticedthat
some of the high-score features recognized in this study are indeed
important structure features observed in the active compounds.
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Fig. 4. The distribution of PubChem ﬁngerprint score of the compounds
according to the contribution to the classiﬁcation.
For example, the feature of C(∼N)(∼N) (no. 6 in Table S1 in the
Supplementary Material), is part of the scaffold of benzimidazole
analogs, one luciferase inhibitor cluster; the features of C:S:C-C and
S-C:C-N (no. 24, 30 in Table S1 in the Supplementary Material) are
part of the scaffold of 2-Phenylbenzothiazole analogs (Auld et al.,
2008; 2009). Thus, this work may provide useful insights into the
structure components critical for luciferase inhibition activity.
4 DISCUSSION
One of the main difﬁculties of working with HTS data arises from
the fact that HTS data is highly imbalanced with only a handful
of hits identiﬁed often out of a huge amount of tested compounds
(Fig. S1 in the Supplementary Material). Most of the HTS assays in
PubChem screened a large library of chemical compounds, where
onlyasmallfractionofthetestedcompoundswereconsideredashits
and reported ‘active’ in PubChem. A distribution of the imbalance
ratios of 258 distinct HTS assays in PubChem deposited by the NIH
Chemical Genomics Center (NCGC) is shown in Figure S1 in the
Supplementary Material, from which we observed almost ratios are
under 1/10. Here, we investigated an approach for building an SVM
model on the highly imbalanced dataset of the luciferase inhibition
HTS assay in PubChem (PubChem AID: 773, 1006 and 1379). The
bestSVMmodelsuccessfullydistinguishedtheactivecompoundsat
anaccuracyof86.60%andtheinactivecompoundsatanaccuracyof
88.89%, with a total accuracy of 87.74% by critical evaluation test.
Ideally, the standard SVM draws an optimal hyperplane to
separate positive data from negative data with maximum distance.
However, the SVM model that is constructed from an imbalanced
dataset tends to draw the hyperplane away from the ideal place
and towards the minority side. Thus, the model is likely to classify
most objects into the majority class, leading to great disparity
between speciﬁcity and sensitivity, regardless of the parameter
optimization. As a result, the predictability of such a model can
be substantially poor.
The GSVM-RU method, which is based on the statistical learning
theory (Corinna and Vapnik, 1995), to under sample the majority
class and minimize the information loss of the majority class,
Fig. 5. Blind test results of each model over the sampling process. The
squares in the solid line (blue) represent the G-mean values. The circles in
the dashed line (green) and the triangles in the dotted line (red) represent
speciﬁcity and sensitivity, respectively.
achieved good performances on imbalanced HTS data. To look into
the progress of the sampling process, we not only built the ﬁnal
well-optimized RBF SVM model based on the converged sampling
results at sampling round 67, but also built a SVM model on the
sampled compounds at the end of each round of sampling process.
For each round of the sampling, we tested the performance of the
constructed SVM model with the blind test dataset, which contained
97 active compounds and 36733 inactive compounds that all were
excluded from the sampling process (Fig. 5). The initial model
was able to recognize the inactive compounds very well at the
accuracy of >90%, while it could only correctly classify the active
compounds at accuracy of 60% or even less at the beginning.As the
sampling process proceeded, however, the ability of the SVM model
to recognize the active compounds increased dramatically from
<60% to >85% after certain steps. These observations agreed well
with the results in sampling process. Meanwhile, the discrimination
of inactive compounds only decreased ∼5%. These results indicate
that the hyperplane of the SVM model moved gradually from the
minority class side towards to the majority class side (negative
samples), in other words, it was pulled back to the ideal place.
The entire recognition ability (G-mean value) of the SVM model
increased from ∼7 0%t o>87.74%.
Another concern is the evaluation metrics selection when
evaluating statistical models built on HTS data. Some of the
commonly used metrics, such as overall accuracy [equation (3)],
can lead to poor predictability when they are used for evaluating
models built on imbalanced datasets as the evaluation metrics are
dependent on the data distribution. Indeed, using inappropriate
metrics is another reason for prediction distortion when optimizing
model on imbalanced data. For instance, for a dataset with the
positive/negative sample ratio of 1/9, although all samples are
predicted to be negative, the overall accuracy is still 90%. For
this reason that we used G-mean value and ROC curve, which are
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independent of the data distribution, to evaluate the performance of
the SVM.
Furthermore, the size of HTS data, which usually contains
hundreds of thousands of compounds, presents another challenge.
Training and optimizing a statistical model on such a large dataset
can be extremely time-consuming. The undersampling method
in this study was computationally efﬁcient, and it successfully
downsized the dataset from more than one hundred thousand
compounds to several hundreds of compounds, thus greatly reduced
the computational cost in the optimized process and signiﬁcantly
increasing the efﬁciency of the SVM model. In other words, the
GSVM-RU method provides a strategy for data sampling or data
cleaning of a big dataset.
In addition, due to experimental conditions or the complexity
of the biological system, there may be a certain amount of false
positives and false negative data in HTS assays.We found that assay
bioactivity results for certain compounds conﬂicted with each other
even when they were provided by the same laboratory. For this
reason, we carefully prepared the dataset in our study and used only
compounds with bioactivity outcome, i.e. active versus inactive,
which were conﬁrmed by at least two assays.
Chemical space coverage is indeed an important issue in
cheminformatics research. The chemical space coverage was
estimated based on 2D chemical structure similarity using Tanimoto
score of 0.90 as the threshold. Of the active compounds, 88.30% in
the dataset are similar to the active compounds used in the model
building, while ∼1.4% of the inactive compounds in the entire
datasetaresimilartooneormoreoftheinactivecompoundsselected
by the sampling procedure. The high coverage of active compounds
indicates a strong structure–active relationship (SAR) among this
group of compounds. Unlike the traditional clustering methods,
such as k-mean, which ﬁnds the most featured representatives of
a class, the strategy of the GSVM-RU method used in this study
is to ﬁnd the samples close to the border between two classes,
which are used to draw the separating hyperplane. It means the other
samples far away from hyperplane are discarded when a model is
built. The entire training dataset was used in the searching of the
optimized hyperplane. The ﬁnal coverage (1.4%) for the ‘inactive’
compounds was calculated using the samples close to the separating
hyperplane which were derived at the end of the sampling process.
Theconﬁdenceofthepredictionofacompoundisproportionaltothe
distance to the hyperplane.The distribution of the blind test samples
are shown in Figure 3, from which we observed that compounds that
were not correctly predicted are basically close to the hyperplane. In
addition, we also investigated the chemical property space coverage
and plotted the distribution of rule of ﬁve properties (molecular
weight, XlogP, hydrogen donor, hydrogen acceptor) for this dataset
as shown in Figure S2 in the Supplementary Material, which is
coincident with the distribution of the bioactive molecules observed
in another work (Frimurer et al., 2000).
We used PubChem 2D ﬁngerprints to characterize chemical
compounds. A PubChem ﬁngerprint indicates the presence/absence
of a certain chemical feature in a studied compound. As the 881
features did not make equal contribution to the classiﬁcation, we
further carried out a feature selection to reduce potential data
noise, though no signiﬁcant improvement of the model performance
has been achieved on this regard. We used the default PubChem
ﬁngerprint as the chemical structure descriptor in this study for it is
readily available for public usage. We anticipate that a combination
with some other molecular descriptors might further improve the
classiﬁcation performance and help to identify the relationship
between a molecular structure and its biological activity. We plan to
evaluate this factor in the future study by combining other molecular
descriptors, including 3D molecular descriptors. Bioluminescent
assays are a popular technology used in HTS experiments (Fan and
Wood, 2007). Luciferase inhibition is one of the main sources of
interference in such assays, which causes artifacts, and complicates
the interpretation of the experimental data and the identiﬁcation of
HTS hits (Auld et al., 2008, 2009). Development of a computational
tool which could facilitate the selection of chemical compounds
for HTS screening and assist the interpretation of the resulting
bioassay data was another motivation of this study. Several large-
scale HTS experimental results of luciferase inhibitor screening
have recently been deposited in the PubChem BioAssay database.
The satisfactory performances in both cross-validation and blind
test process have demonstrated the good generalization of the SVM
model developed in this study, and suggests its potential application
in virtual screening for compounds with luciferase inhibition or
other types of biological activity. It needs to be pointed out that the
development of the model is a learning process. Thus, the potential
of the developed model is intrinsically limited to the known active
compounds and the properties used for training. With the growth
of the additional chemical classes of compounds to be screened,
a more robust model may be developed with the availability of
biologically interesting small molecules from a diverse compound
library.
5 CONCLUSION
In this study, we used the GSVM-RU method to construct a SVM
model on the extremely imbalanced HTS data [the imbalance
ratio of 1:377 (active/inactive)] obtained from several luciferase
inhibitor assays in PubChem. The best model recognized the active
and inactive compounds at the accuracies of 86.60 and 88.89%,
respectively, with an accuracy of 87.74% in critical evaluation.
These results demonstrate the robustness of the model in handling
the intrinsic imbalance problem in HTS data and indicate that the
model can be used as a virtual screening tool to identify potential
interference compounds in luciferase-based HTS experiments.
Additionally, this method has also proved computationally efﬁcient
bygreatlyreducingthecomputationalcostandcanbeeasilyadopted
in the analysis and interpretation of HTS data for other biological
systems.
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